Silex

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Silex

Property Description
Active ingredient Cefepime (as hydrochloride)
Form Sterile powder for injection
Pharmacological class Fourth-generation Cephalosporin Antibiotic
Common use Systemic Anti-Infective
Origin Synthetic

What Type of Antibiotic is Silex?

Silex is a prescription-only medicine classified as a powerful fourth-generation cephalosporin, which is a class of synthetic beta-lactam antibiotics. The active substance is Cefepime hydrochloride. Cefepime is effective against a wide range of bacteria and is classified as a broad-spectrum agent. This capability is based on its stability against common bacterial resistance mechanisms. As a synthetic compound, Cefepime is engineered for high reliability and consistency. The fourth-generation status signifies that its chemical structure provides enhanced capability over earlier-generation cephalosporins, making it suitable for treating infections where resistance is a significant concern.


Silex Composition and General Purpose

Silex is supplied as a sterile powder for injection, which is reconstituted into a solution for injection for parenteral administration, and its general purpose is to combat serious systemic bacterial infections. This formulation is administered directly into the bloodstream (parenterally) to achieve high concentrations quickly. The active ingredient, Cefepime hydrochloride, works by a mechanism known as bactericidal action. This mechanism involves actively disrupting the growth and integrity of the bacterial cell wall, which causes the pathogen to die. Consequently, this drug's primary function is to eliminate the bacterial cause of the infection rather than simply slowing its growth, which is typically crucial in managing severe or complicated infections requiring systemic antimicrobial intervention.

Regulatory References

  1. Cefepime MeSH Descriptor Data

What side effects are possible with Silex?

Possible Side Effects and Safety Information

The official safety profile for Silex (Cefepime) is defined by a range of documented adverse reactions classified by frequency and the body system affected, strictly according to governmental regulatory documents.

Frequency-Classified Adverse Reactions

The likelihood of adverse reactions is formally categorized in regulatory labeling:

  • Very Common (ge 1/10): A positive Coombs' test, which is a laboratory finding.
  • Common (ge 1/100 to < 1/10): Diarrhoea, rash, eosinophilia, and local reactions such as phlebitis or pain at the injection site. Increases in certain liver enzymes (ALT and AST) are also common.
  • Uncommon (ge 1/1,000 to < 1/100): Includes vomiting, pseudomembranous colitis, urticaria, and changes in blood cell counts (thrombocytopenia, leukopenia).

Serious Adverse Reactions and Safety Considerations

The regulatory profile highlights several serious adverse reactions, notably Neurotoxicity (including encephalopathy, seizures, stupor, or coma), which is primarily associated with this class of medication.

Another serious reaction is Clostridioides difficile-Associated Diarrhea (CDAD), which can range from mild symptoms to fatal colitis. Severe hypersensitivity reactions, including anaphylaxis, are also documented.

Specific safety considerations exist for certain populations. Patients with impaired kidney function and older adults are at a significantly heightened risk for the serious neurological adverse reactions if dosage adjustments are not made according to the official prescribing information. Use is strictly restricted in individuals with a known hypersensitivity to Cefepime, cephalosporins, penicillins, or other beta-lactam antibiotics due to the risk of cross-hypersensitivity.

Overdose and Emergency Response

The regulatory documentation for Silex (Cefepime) defines overdosage primarily through its neurological manifestations and specific risk factors. Officially documented signs of overexposure are severe central nervous system effects, including encephalopathy—which presents as confusion, hallucinations, stupor, or coma—myoclonus (muscle shaking), and seizures, including nonconvulsive status epilepticus. Aphasia and general neuromuscular excitability have also been observed. In severe, unmanaged cases, these neurological events have been reported as life-threatening or fatal.

Immediate emergency action is required for any severe symptom. Regulatory authorities advise to immediately call emergency services if the affected individual collapses, has trouble breathing, or cannot be awakened. Medical attention must also be sought right away for sudden signs of nonconvulsive status epilepticus. The drug must be discontinued if neurotoxicity is observed.

A significant risk factor is the presence of compromised renal function, as high and prolonged serum concentrations can lead to neurotoxicity even when standard doses are used, particularly in geriatric patients. The official management of overdosage includes careful observation, symptomatic and supportive treatment, and the use of hemodialysis to aid in drug removal. Official labeling specifies that peritoneal dialysis is of no value for this purpose.

Therapeutic Uses of Silex

What Silex Treats: Main Uses and Benefits

Silex is generally used as a broad-spectrum anti-infective agent applied in clinical settings that involve acute or unstable symptom patterns. The medication is relevant across domains where additional symptomatic support is needed to support the patient during difficult episodes by easing distress; it is commonly used to help manage severe conditions such as pneumonia, complicated urinary tract infections (including pyelonephritis), skin structure infections, intra-abdominal infections, bacteremia, and febrile neutropenia.

Its core purpose is to address symptom clusters that may become intense or disruptive, such as high fever and localized strain in organs, and is relevant for managing symptoms linked to the bacterial issue. This support helps ease the overall symptom burden associated with systemic imbalance, and helps patients cope more steadily with symptom fluctuations.

“This intervention is commonly used to help manage symptoms linked to life-threatening bacterial infections and is relevant for easing distress in critically ill patients.”


Quick Fact: Support for Acute Systemic Symptoms

Silex is commonly used during phases when symptoms become more noticeable, contributing to easing the overall symptom load related to systemic imbalance, particularly fever and generalized distress in patients with complicated or high-risk infections.

Regulatory References

  1. Cefepime Injection: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Silex (Cefepime) — Official Regulatory Information

Official regulatory labeling defines eligibility for Silex (Cefepime) by identifying populations who are eligible under standard conditions, those who are strictly prohibited, and those who require conditional use based on physiological status.


Eligibility Scope Status according to Regulatory Documents
Populations for whom use is contraindicated Patients with a known history of immediate hypersensitivity to Cefepime, any cephalosporin antibiotic, or other severe beta-lactam antibiotics (e.g., penicillins) are strictly ineligible.
Age-related eligibility rules Use is approved for adults and pediatric patients from 2 months of age and older. Safety and efficacy have not been established for infants under 2 months. Geriatric patients (65 and older) are eligible but require caution and monitoring of kidney function.
Condition-specific eligibility rules Patients with renal impairment (Creatinine Clearance le 60 mL/min) are subject to conditional use. This conditional status requires adjustment due to the risk of accumulation and associated neurotoxicity. The drug is permitted for patients with hepatic impairment.
Pregnancy and lactation eligibility status Use during pregnancy (formerly FDA Category B) is conditional and should occur only if clearly needed. Cefepime is excreted into human milk, making its use during lactation conditional, where caution is advised.

Official eligibility statements:

  • The medicine is contraindicated in patients with documented severe hypersensitivity to Cefepime or related antibiotics.
  • Safety and effectiveness have not been established in pediatric patients younger than 2 months of age.
  • Use in patients with renal impairment must be restricted and managed due to regulatory requirements related to drug clearance.

Connection to the overall eligibility profile:

Official regulatory documents establish absolute exclusions based on a patient’s immunological history and institute conditional use based on organ function and age group. These criteria determine who can safely receive the medicine by ensuring that only populations with documented safety profiles or those where risks can be specifically managed are eligible for treatment.

What should I know about interactions with other medicines?

Silex Interactions with other medicines and products

The official interaction profile for Silex is strictly documented by regulatory authorities and focuses on pharmacokinetic alterations and additive toxicity risks.

Category Official Regulatory Statement
Pharmacodynamic Interactions Co-administration with Aminoglycosides increases the potential for nephrotoxicity and ototoxicity. Nephrotoxicity has also been reported following the co-administration of potent diuretics (such as Furosemide) with other cephalosporins.
Pharmacokinetic Interactions (Exposure) Agents that inhibit renal tubular secretion, such as Probenecid, may decrease the renal clearance of Cefepime, resulting in increased plasma concentrations of the medicine.
Population-Specific Interaction Reduced clearance in Renal Impairment results in increased systemic exposure, which is associated with a risk of dose-related neurotoxicity.
Contraindication The medicine is strictly contraindicated in patients with a history of immediate hypersensitivity to Cefepime, any cephalosporin, penicillins, or other beta-lactam antibacterial drugs.
Laboratory Test Interference Administration may cause a false-positive reaction for glucose in the urine when using copper reduction methods (e.g., Clinitest tablets) and may result in a Positive Direct Coombs' Test.

The official regulatory documents define the interaction profile of Silex primarily through concerns related to its elimination pathway. The structure formally documents the risks of additive organ toxicity with nephrotoxic agents and the restriction on combination with substances that inhibit renal clearance, leading to elevated exposure. The profile further includes constraints regarding interference with standard laboratory diagnostics.

Mechanism of Action

The core mechanism acts by covalently binding to Penicillin-Binding Proteins (PBPs), which are bacterial enzymes essential for synthesizing the rigid cell wall. This specific inhibition arrests the final peptidoglycan cross-linking step, leading to a direct and profound structural defect in the bacterial cell. This disruption immediately triggers the pathogen's own self-destruct mechanism (autolysins), resulting in rapid cell lysis and a bactericidal physiological effect across susceptible microbial populations.

This inhibitory action is sustained because the drug’s structure confers stability against many bacterial beta-Lactamase enzymes, a primary deactivation pathway. This structural feature allows the drug molecule to bypass these enzymatic defenses and engage its PBP target, supporting the delivery of a consistent inhibitory action.

However, the mechanism is constrained by bacterial modification of PBP target sites or activation of efflux pumps. A secondary, off-target interaction at human GABA-A receptors in the central nervous system also influences the maximum systemic concentration achievable before neurological physiological responses are affected.

Dosage and Administration Information

Silex (Cefepime) is an antibiotic strictly administered via the parenteral route, primarily through intravenous (IV) infusion, but used for IV injection or intramuscular (IM) injection in certain contexts. The medicine is a sterile powder that is reconstituted with a specified diluent, such as Sterile Water for Injection, before administration. When delivered as an IV infusion, the administration time is standardized to approximately 30 minutes.

The standard adult dosing regimen ranges from 500 mg to 2 g per dose, with administration occurring at fixed intervals of either every 12 hours (q12h) or every 8 hours (q8h), depending on the schedule for the infection type. The maximum recommended daily dose for severe conditions is typically 6 grams. The overall duration of treatment often spans 7 to 14 days.

A core principle of Silex usage is the adjustment of the dose in patients with renal impairment (kidney function decline). For patients with a Creatinine Clearance less than or equal to 60 mL/min, a reduced dose and/or extended interval is applied, including specific regimens for those on hemodialysis. For pediatric patients (2 months to 16 years), the dosage is calculated based on body weight (mg/kg), but the total dose does not exceed the maximum adult dosage.

Recent Clinical Evidence

Silex: Recent Clinical Evidence

Silex (SIL204) is currently an investigational drug, a next-generation RNA interference (RNAi) therapy being developed to address solid tumors characterized by KRAS gene mutations. The research involves a planned progression through clinical trials, focusing initially on locally advanced pancreatic cancer (LAPC) and other KRAS-driven cancers.


Findings from Preclinical Studies

Recent data from preclinical (laboratory and animal) studies for SIL204 have been reported, primarily utilizing human cancer cell lines and orthotopic animal models. These models are designed to mimic human disease more closely than standard laboratory xenografts, particularly in the context of metastatic spread.

  • Pancreatic Cancer Models: In orthotopic mouse models of pancreatic cancer, systemic administration of SIL204 was associated with a reduction in both the primary tumor size and the extent of cancer spread (metastases) to secondary organs. One study reported a reduction in tumor growth, measured by bioluminescence, compared to a control group over a 14-day observation period.
  • Broad Activity: Further laboratory testing using human cell lines from five different cancer sites, including lung, colorectal, and gastric cancers, demonstrated activity against a range of clinically significant KRAS mutations. The degree of observed inhibition in cell proliferation varied across the different cell lines tested.

Clinical Development Status

Clinical trials are necessary to determine if the findings observed in preclinical studies translate to a measurable effect in human patients. Silexion Therapeutics' first-generation product, LODER™, was previously evaluated in a Phase 2a clinical trial for non-resectable pancreatic cancer, showing a positive numerical trend when compared to chemotherapy alone.

Trial Stage Compound Focus Area Status
Phase 2a LODER™ Non-resectable Pancreatic Cancer Data collection complete
Phase 2/3 (Planned) SIL204 KRAS-driven Solid Tumors Scheduled for initiation in 2026

The company is preparing for the initiation of a Phase 2/3 trial for SIL204. The design for this next stage of research has received formal scientific advice from a German health authority (BfArM), which supports the acceptability of the proposed study design and manufacturing specifications. The initiation of the trial is pending regulatory clearances.

Frequently Asked Questions (FAQ)

Common questions about Silex (FAQ)

Q: What is the main condition Silex is approved to treat?

A: According to official regulatory documents, Silex (Cefepime) is an antibiotic approved for treating several serious bacterial infections.

These include certain types of pneumonia, complicated and uncomplicated urinary tract infections, and various intra-abdominal and skin structure infections. It is also indicated for the initial, or empiric, treatment of fever in patients with febrile neutropenia.

Q: How long does it usually take for Silex to reach its full effect according to clinical data?

A: The time needed to fully resolve an infection depends on the specific condition being treated. Official prescribing information states that the required course of treatment for most conditions is generally 7 to 14 days.

Official information emphasizes the importance of completing the full duration prescribed to support the achievement of the full therapeutic effect against the infection.

Q: Are the initial side effects of Silex likely to improve over time?

A: Regulatory sources do not provide a definitive timeline for the resolution of all initial side effects. The official information does note that symptoms of neurotoxicity, a serious safety concern, typically begin four days after starting the medication.

If you experience any concerning side effects, it is appropriate to notify your healthcare provider.

Q: Is it common for users to experience mild nausea when first starting Silex?

A: Yes, nausea is listed as a common adverse reaction in the official safety profile of Silex, meaning it is reported in at least 1% of users.

This side effect is observed particularly when the drug is administered at the highest dosage levels.

Q: Does Silex carry a specific 'Black Box Warning' or special alert from regulatory bodies?

A: The FDA label includes a prominent warning regarding the risk of neurotoxicity (a serious effect on the nervous system).

This alert emphasizes the risk of symptoms like seizures and confusion, especially in patients with reduced kidney function whose dose has not been adjusted appropriately.

Q: Can Silex cause drowsiness or affect a person's ability to drive?

A: Official safety information indicates that Silex is associated with neurotoxicity, which can cause symptoms such as confusion, seizures, and severe sleepiness.

Given these potential effects on the central nervous system, activities requiring full mental alertness, such as driving, may be impacted.

Q: Are there any known long-term safety concerns associated with taking Silex for several years?

A: Silex (Cefepime) is an antibiotic prescribed for short courses of 7 to 14 days and is not intended for use over several years.

Official sources advise against prolonged use, as it can increase the risk of certain bacterial overgrowths leading to a superinfection, such as Clostridioides difficile-associated diarrhea.

Q: Are there any effects of Silex on sleep patterns?

A: The drug is associated with a serious side effect called neurotoxicity, which affects the central nervous system.

This neurological risk can manifest as symptoms including severe sleepiness or stupor (a state of near-unconsciousness).

Q: Can Silex be taken with a general over-the-counter painkiller like ibuprofen?

A: Regulatory interaction checks advise caution regarding the combination of Silex with certain nonsteroidal anti-inflammatory drugs (NSAIDs).

The concern is that combining these medications may increase the risk of nephrotoxicity, which is damage to the kidneys.

Q: Does Silex interact with other common medications, such as blood pressure drugs?

A: Yes, official regulatory labeling documents interactions with certain medications, including blood pressure drugs that act as potent diuretics (such as Furosemide).

Co-administration with potent diuretics has been associated with an increased potential for nephrotoxicity (kidney damage) when used with other cephalosporins.

Q: Does Silex interact with common antidepressant or anxiety medications?

A: Regulatory interaction data indicates that Silex may affect the body's process for eliminating some antidepressant and anti-anxiety medications.

This potential interaction could result in higher levels of those drugs remaining in the bloodstream.

Q: Are there any known effects of Silex on male or female fertility?

A: There is information available from nonclinical studies regarding this topic.

Official reports state that animal studies conducted on Cefepime failed to reveal any evidence of impairment to fertility or reproductive toxicity.

Q: Does Silex require specific monitoring, such as regular blood tests, while in use?

A: Official patient information notes that regular monitoring of the patient's progress is often conducted by the healthcare provider during treatment with Silex.

This monitoring may include certain laboratory tests to check the drug’s effects and ensure proper clearance, especially since the drug is eliminated through the kidneys.

Q: Does the evidence indicate a difference in how Silex works in different demographic groups?

A: The drug’s fundamental mechanism of action is consistent across all groups.

However, official documents highlight that dosage must be precisely adjusted for older adults and patients with impaired kidney function due to reduced drug clearance and risk of neurological adverse reactions.

Q: Is Silex considered to be a medication with a risk of dependence or addiction?

A: No, Silex (Cefepime) is a prescription antibiotic used to treat bacterial infections.

It is not classified as a controlled substance and is not associated with a risk of dependence or abuse.

Q: What is the recommended guidance if someone accidentally stops taking Silex abruptly?

A: Regulatory guidance emphasizes the importance of completing the entire prescribed course, even if symptoms begin to improve.

This practice is necessary to fully eliminate the infection and prevent the bacteria from becoming resistant to the antibiotic.

Q: Is there a known antidote or specific treatment for an accidental overdose of Silex?

A: In the event of an accidental overdose, the official regulatory label notes that a major portion of Silex can be removed from the body using hemodialysis.

Hemodialysis is a blood purification procedure often used when the kidneys cannot adequately clear substances from the body.

Q: What does the evidence say about the expected benefits for long-term Silex use?

A: Official guidance relates to short treatment courses, typically 7 to 14 days.

Prolonged use is not recommended because it can lead to an increased risk of specific bacterial overgrowth and a secondary infection called superinfection.

Q: How long does it takes for Silex to be completely eliminated from the body?

A: The time it takes for Silex to be eliminated is directly tied to kidney function.

In individuals with normal kidney function, the drug's half-life (the time it takes for the amount in the body to drop by half) is approximately 2 hours. This half-life is significantly extended in patients with reduced kidney function.

Q: What is the official guidance if a dose of Silex is missed?

A: Official guidance provides that a missed dose may be administered as soon as it is remembered.

However, if the time is near for the next scheduled dose, the regulatory information indicates the missed dose is generally to be skipped to avoid a double dose.

Q: Is the effectiveness of Silex affected by body weight or body mass index?

A: Official information indicates that, for pediatric patients between 2 months and 16 years of age, the dosage is calculated based on body weight ( mg/ kg).

There is no specific official statement relating adult body weight or BMI to the drug's effectiveness.

Q: Why must Silex be taken exactly as described in the official instructions, even if I feel better?

A: Official guidance underscores the importance of taking the medicine exactly as prescribed, even if symptoms improve quickly.

This practice ensures the infection is completely treated and significantly reduces the possibility of the bacteria developing resistance to the antibiotic.

How should Silex be stored and disposed of?

How to Store and Dispose of Silex (Cefepime for Injection)

The storage and disposal instructions for Silex are mandatory conditions required by regulatory labeling to maintain the product’s integrity.


Storage Requirements

The sterile powder must be stored at Controlled Room Temperature, specifically 20, C to 25, C, and must be protected from light by being kept in its original package. The product must be stored out of the sight and reach of children. Once the powder is reconstituted, the solution is stable for 24 hours at room temperature or for up to 7 days when refrigerated (2, C to 8, C), but it must not be frozen.


Disposal Requirements

Unused or expired Silex and related waste should not be disposed of via wastewater or household waste. Disposal must be performed in accordance with local requirements, often involving return to a pharmacy or an approved local waste disposal company. Used needles and syringes must also be disposed of safely and appropriately.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Silex found in:

A-Z Index: